轻至中度COVID-19康复后的哮喘控制:从Omicron BA.2到XBB-来自香港一所大学医院的队列

IF 2.6 3区 医学 Q2 RESPIRATORY SYSTEM
Wang Chun Kwok, Chung Ki Tsui, Terence Chi Chun Tam, David Chi Leung Lam, Mary Sau Man Ip, James Chung Man Ho
{"title":"轻至中度COVID-19康复后的哮喘控制:从Omicron BA.2到XBB-来自香港一所大学医院的队列","authors":"Wang Chun Kwok, Chung Ki Tsui, Terence Chi Chun Tam, David Chi Leung Lam, Mary Sau Man Ip, James Chung Man Ho","doi":"10.1186/s12890-025-03543-x","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>At the time of Omicron BA.2 outbreak, it was shown that mild to moderate COVID-19 was associated with worsening of asthma control after recovery. Whether the same phenomenon was also observed at a later phase of COVID-19 pandemic by other variants have not been reported.</p><p><strong>Methods: </strong>We conducted a follow-up study on patients with asthma who received clinical care in Queen Mary Hospital. The patients were first recruited in the study entitled \"Worsening of asthma control after recovery from mild to moderate COVID-19 in patients from Hong Kong\". The primary outcome was the asthma control test (ACT) score difference among the patients who never had COVID-19 (no COVID-19 group), patients who had COVID-19 diagnosed in the initial study (past COVID-19 group) and patients who had COVID-19 diagnosed in the follow-up period (new COVID-19 group) of the current study.</p><p><strong>Results: </strong>189 patients were included. The change of ACT score from the last visit in the previous study to the last follow-up visit in current study was - 0.34 ± 3.7 in the no COVID-19 group, -0.0 ± 5.0 in the past COVID-19 group and - 0.17 ± 4.5 in the new COVID-19 group (p = 0.94). There were 10 (24.4%), 24 (25.5%) and 12 (22.2%) patients in the no COVID-19, past COVID-19 and new COVID-19 group who had worsening of asthma control by an increase in ACT score ≥ 3 from the last visit in the previous study to the last follow-up visit in current study (p = 0.90).</p><p><strong>Conclusion: </strong>Patients who had COVID-19 in 2023 with Omicron XBB as the dominant strain did not have worsening of asthma control seen in previous study done in 2022 with Omicron BA.2 as the circulating strain. Patients who had worsening of asthma control after COVID-19 in 2022 had subsequent improvement of asthma control with longer follow-up interval.</p>","PeriodicalId":9148,"journal":{"name":"BMC Pulmonary Medicine","volume":"25 1","pages":"74"},"PeriodicalIF":2.6000,"publicationDate":"2025-02-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11816497/pdf/","citationCount":"0","resultStr":"{\"title\":\"Asthma control after recovery from mild to moderate COVID-19: from Omicron BA.2 to XBB- from a cohort in a university hospital in Hong Kong.\",\"authors\":\"Wang Chun Kwok, Chung Ki Tsui, Terence Chi Chun Tam, David Chi Leung Lam, Mary Sau Man Ip, James Chung Man Ho\",\"doi\":\"10.1186/s12890-025-03543-x\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>At the time of Omicron BA.2 outbreak, it was shown that mild to moderate COVID-19 was associated with worsening of asthma control after recovery. Whether the same phenomenon was also observed at a later phase of COVID-19 pandemic by other variants have not been reported.</p><p><strong>Methods: </strong>We conducted a follow-up study on patients with asthma who received clinical care in Queen Mary Hospital. The patients were first recruited in the study entitled \\\"Worsening of asthma control after recovery from mild to moderate COVID-19 in patients from Hong Kong\\\". The primary outcome was the asthma control test (ACT) score difference among the patients who never had COVID-19 (no COVID-19 group), patients who had COVID-19 diagnosed in the initial study (past COVID-19 group) and patients who had COVID-19 diagnosed in the follow-up period (new COVID-19 group) of the current study.</p><p><strong>Results: </strong>189 patients were included. The change of ACT score from the last visit in the previous study to the last follow-up visit in current study was - 0.34 ± 3.7 in the no COVID-19 group, -0.0 ± 5.0 in the past COVID-19 group and - 0.17 ± 4.5 in the new COVID-19 group (p = 0.94). There were 10 (24.4%), 24 (25.5%) and 12 (22.2%) patients in the no COVID-19, past COVID-19 and new COVID-19 group who had worsening of asthma control by an increase in ACT score ≥ 3 from the last visit in the previous study to the last follow-up visit in current study (p = 0.90).</p><p><strong>Conclusion: </strong>Patients who had COVID-19 in 2023 with Omicron XBB as the dominant strain did not have worsening of asthma control seen in previous study done in 2022 with Omicron BA.2 as the circulating strain. Patients who had worsening of asthma control after COVID-19 in 2022 had subsequent improvement of asthma control with longer follow-up interval.</p>\",\"PeriodicalId\":9148,\"journal\":{\"name\":\"BMC Pulmonary Medicine\",\"volume\":\"25 1\",\"pages\":\"74\"},\"PeriodicalIF\":2.6000,\"publicationDate\":\"2025-02-11\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11816497/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"BMC Pulmonary Medicine\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1186/s12890-025-03543-x\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"RESPIRATORY SYSTEM\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"BMC Pulmonary Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s12890-025-03543-x","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"RESPIRATORY SYSTEM","Score":null,"Total":0}
引用次数: 0

摘要

背景:在Omicron BA.2爆发时,有研究表明轻至中度COVID-19与康复后哮喘控制恶化相关。在COVID-19大流行的后期阶段,其他变异是否也观察到同样的现象,尚未有报道。方法:对在玛丽医院接受临床治疗的哮喘患者进行随访研究。这些患者最初是在名为“香港患者轻至中度COVID-19康复后哮喘控制恶化”的研究中招募的。主要观察指标为未患COVID-19患者(无COVID-19组)、初始研究中诊断为COVID-19的患者(既往COVID-19组)和本研究随访期诊断为COVID-19的患者(新COVID-19组)的哮喘控制测试(ACT)评分差异。结果:共纳入189例患者。既往研究末次随访至本次研究末次随访ACT评分变化:无COVID-19组为- 0.34±3.7分,既往COVID-19组为-0.0±5.0分,新冠肺炎组为- 0.17±4.5分(p = 0.94)。无COVID-19、既往COVID-19和新发COVID-19组中,有10例(24.4%)、24例(25.5%)和12例(22.2%)患者从既往研究末次随访到本研究末次随访ACT评分升高≥3,哮喘控制恶化(p = 0.90)。结论:在2023年以Omicron XBB为优势菌株的COVID-19患者中,与之前在2022年以Omicron BA.2为循环菌株的研究相比,哮喘控制没有恶化。2022年新冠肺炎后哮喘控制恶化的患者,后续哮喘控制改善,随访时间延长。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Asthma control after recovery from mild to moderate COVID-19: from Omicron BA.2 to XBB- from a cohort in a university hospital in Hong Kong.

Background: At the time of Omicron BA.2 outbreak, it was shown that mild to moderate COVID-19 was associated with worsening of asthma control after recovery. Whether the same phenomenon was also observed at a later phase of COVID-19 pandemic by other variants have not been reported.

Methods: We conducted a follow-up study on patients with asthma who received clinical care in Queen Mary Hospital. The patients were first recruited in the study entitled "Worsening of asthma control after recovery from mild to moderate COVID-19 in patients from Hong Kong". The primary outcome was the asthma control test (ACT) score difference among the patients who never had COVID-19 (no COVID-19 group), patients who had COVID-19 diagnosed in the initial study (past COVID-19 group) and patients who had COVID-19 diagnosed in the follow-up period (new COVID-19 group) of the current study.

Results: 189 patients were included. The change of ACT score from the last visit in the previous study to the last follow-up visit in current study was - 0.34 ± 3.7 in the no COVID-19 group, -0.0 ± 5.0 in the past COVID-19 group and - 0.17 ± 4.5 in the new COVID-19 group (p = 0.94). There were 10 (24.4%), 24 (25.5%) and 12 (22.2%) patients in the no COVID-19, past COVID-19 and new COVID-19 group who had worsening of asthma control by an increase in ACT score ≥ 3 from the last visit in the previous study to the last follow-up visit in current study (p = 0.90).

Conclusion: Patients who had COVID-19 in 2023 with Omicron XBB as the dominant strain did not have worsening of asthma control seen in previous study done in 2022 with Omicron BA.2 as the circulating strain. Patients who had worsening of asthma control after COVID-19 in 2022 had subsequent improvement of asthma control with longer follow-up interval.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
BMC Pulmonary Medicine
BMC Pulmonary Medicine RESPIRATORY SYSTEM-
CiteScore
4.40
自引率
3.20%
发文量
423
审稿时长
6-12 weeks
期刊介绍: BMC Pulmonary Medicine is an open access, peer-reviewed journal that considers articles on all aspects of the prevention, diagnosis and management of pulmonary and associated disorders, as well as related molecular genetics, pathophysiology, and epidemiology.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信